Jia Zhen-Wei, Li Yan, Cui Gui-Rong, Zhao Hong-Bo, Li Pei-Yin, Luo Jian-Min
Department of Hematology, Handan First Hospital, Handan 056002, Hebei Province,China.
Department of Hematology, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Jun;26(3):653-657. doi: 10.7534/j.issn.1009-2137.2018.03.004.
To investigate the expression of LncRNA KCNQ1OT1 in patients with acute myeloid leukemia (AML) and to analyze the relation of LncRNA KCNQ1OT1 expression levels with clinicopathological features.
A total of 68 patients with AML were enrolled in the study, 48 out of them were suffered from acute myeloid leukemia (AML) and 20 reached to complete remission (CR), 30 age-matched patients with iron-deficient anemia were included in control group, the peripheral blood samples of all the patients were collected, and the real-time fluorescent quantitative PCR (qRT-PCR) was used to detect the expression of LncRNA KCNQ1OT1, meanwhile, the correlation of its expression with clinicopathological characteristics and prognosis was analyzed.
The expression of LncRNA KCNQ1OT1 in AML patients was significantly higher than that in the patient with complete remission and iron-deficient anemia (F=14.67, P<0.01). The expression of LncRNA KCNQ1OT1 was not significantly different between 20 cases of AML-CR and 30 cases of iron-deficient anemia (P>0.05). The expression of LncRNA KCNQ1OT1 was associated with NCCN risk grade and survival status in patients with AML. The median overall survival time was significantly shorter in patients with high expression of LncRNA KCNQ1OT1 than that in patients with low expression(P<0.05).
LncRNA KCNQ1OT1 may be involved in the regulation of AML. Expression of LncRNA KCNQ1OT1 and NCCN risk score can be used as biomarkers of prognosis in the patients with AML and may be a potential prognostic marker and therapeutic target for AML patients.
探讨长链非编码RNA KCNQ1OT1在急性髓系白血病（AML）患者中的表达情况，并分析其表达水平与临床病理特征的关系。
本研究共纳入68例AML患者，其中48例为急性髓系白血病患者，20例达到完全缓解（CR），选取30例年龄匹配的缺铁性贫血患者作为对照组。采集所有患者的外周血样本，采用实时荧光定量PCR（qRT-PCR）检测长链非编码RNA KCNQ1OT1的表达，同时分析其表达与临床病理特征及预后的相关性。
AML患者中长链非编码RNA KCNQ1OT1的表达明显高于完全缓解患者及缺铁性贫血患者（F=14.67，P<0.01）。20例AML-CR患者与30例缺铁性贫血患者长链非编码RNA KCNQ1OT1的表达差异无统计学意义（P>0.05）。长链非编码RNA KCNQ1OT1的表达与AML患者的NCCN风险分级及生存状态相关。长链非编码RNA KCNQ1OT1高表达患者的中位总生存时间明显短于低表达患者（P<0.05）。
长链非编码RNA KCNQ1OT1可能参与AML的调控。长链非编码RNA KCNQ1OT1的表达及NCCN风险评分可作为AML患者预后的生物标志物，可能是AML患者潜在的预后标志物及治疗靶点。
